Boston Scientific Corporation (NYSE:BSX) dropped by -0.37 or -0.09 points during the last session to $22.77 per share. One of the highlights of the day was the net money flow figure, which stood at $7.33 million even as the stock accepted $27.37 million in upticks but rejected $20.04 million in downticks. The up/down ratio for the last observation was a 1.37. The 1-week percentage change for the stock price is registered at 1.22%.A block transaction occurred with $11.52 million in upticks and $1.92 million in downticks while the up/down ratio was calculated to be 6.01. The stock witnessed a net inflow of $9.6 million at the end of the block trade.
The stock has recorded a 20-day Moving Average of 0.04% and the 50-Day Moving Average is 4.66%. The company shares have rallied 27.3% in the past 52 Weeks. On June 9, 2016 The shares registered one year high of $23.35 and one year low was seen on August 24, 2015 at $14.18. The 50-day moving average is $22.49 and the 200 day moving average is recorded at $19.32. S&P 500 has rallied 1.93% during the last 52-weeks.
Boston Scientific Corporation (NYSE:BSX): The stock opened at $22.97 on Tuesday but the bulls could not build on the opening and the stock topped out at $23.02 for the day. The stock traded down to $22.68 during the day, due to lack of any buying support eventually closed down at $22.76 with a loss of -0.39% for the day. The stock had closed at $22.85 on the previous day. The total traded volume was 9,824,932 shares.
Currently the company Insiders own 1.31% of Boston Scientific Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.95% . Institutional Investors own 93.31% of Boston Scientific Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -21.18%. On the companys insider trading activities, The officer (EVP, GC & Chief Admin Officer), of Boston Scientific Corp, Pratt Timothy A. had unloaded 24,229 shares at $22.66 per share in a transaction on June 1, 2016. The total value of transaction was $549,029. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.